MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Thursday, May 9, 2019

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Abstract

BACKGROUND::

Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) (The meaning of ITP) has been identified as a risk.

OBJECTIVE::

To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss postmarketing experience outside clinical trials.

METHODS::

CAMMS223 and Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) I and II investigated two annual courses of alemtuzumab 12 mg (or 24 mg in CAMMS223/CARE-MS II) versus subcutaneous interferon beta-1a three times per week. Patients completing core studies could enroll in an extension. Monthly monitoring for ITP continued until 48 months after the last alemtuzumab infusion.

RESULTS::

Of 1485 alemtuzumab-treated MS patients in the clinical development program, 33 (2.2%) developed ITP (alemtuzumab 12 mg, 24 [2.0%]; alemtuzumab 24 mg, 9 [3.3%]) over median 6.1 years of follow-up after the first infusion; most had a sustained response to first-line ITP therapy with corticosteroids, platelets, and/or intravenous immunoglobulin. All cases occurred within 48 months of the last alemtuzumab infusion. Postmarketing surveillance data suggest that the ITP incidence is not higher in clinical practice than in clinical trials.

CONCLUSION::

Alemtuzumab-associated ITP occurs in approximately 2% of patients and is responsive to therapy. Careful monitoring is key for detection and favorable outcomes.

KEYWORDS:

Alemtuzumab; disease-modifying therapy; immune thrombocytopenia; relapsing-remitting multiple sclerosis; safety
PMID:
 
30785358
 
DOI:
 
10.1177/1352458518816612


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
             
Article Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

The role of iron and myelin in orientation dependent R2 * of white matter.

Abstract

Brain myelin and iron content are important parameters in neurodegenerative diseases such as multiple sclerosis (MS). Both myelin and iron content influence the brain's R2 * relaxation rate. However, their quantification based on R2 * maps requires a realistic tissue model that can be fitted to the measured data. In structures with low myelin content, such as deep gray matter, R2 * shows a linear increase with increasing iron content. In white matter, R2 * is not only affected by iron and myelin but also by the orientation of the myelinated axons with respect to the external magnetic field. Here, we propose a numerical model which incorporates iron and myelin, as well as fibre orientation, to simulate R2 * decay in white matter. Applying our model to fibre orientation-dependent in vivo R2 * data, we are able to determine a unique solution of myelin and iron content in global white matter. We determine an averaged myelin volume fraction of 16.02 ± 2.07% in non-lesional white matter of patients with MS, 17.32 ± 2.20% in matched healthy controls, and 18.19 ± 2.98% in healthy siblings of patients with MS

READ MORE


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

To receive The MS BEACON, e-Newsletter, Click here
------------------------------------------------------
 Article Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Wednesday, May 8, 2019

GENENTECH TO PRESENT NEW OCREVUS (OCRELIZUMAB) DATA ANALYSES SHOWING SIGNIFICANT REDUCTION OF DISABILITY PROGRESSION IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS AT THE AAN ANNUAL MEETING


  • New analyses show the effect of OCREVUS on reducing the risk of disability progression is associated with exposure and lower B-cell levels
  • Long-term data in RMS and PPMS show that earlier treatment with OCREVUS significantly reduced the risk of permanent disability progression
  • Over 100,000 people have been treated with OCREVUS globally, in clinical trial and real-world settings; data presented at the AAN Annual Meeting highlights a consistent and favorable benefit-risk profile
SOUTH SAN FRANCISCO, Calif.--()--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new OCREVUS® (ocrelizumab) data in relapsing and primary progressive multiple sclerosis (MS) were presented at the 71st American Academy of Neurology (AAN) Annual Meeting from May 4-10 in Philadelphia, Pennsylvania. New analyses on OCREVUS show its effect on reducing the risk of disability progression is associated with higher exposure to the medicine and lower B-cell levels, and show the positive impact of OCREVUS in significantly reducing disability progression.
With rapidly growing real-world experience and more than 100,000 patients treated globally, OCREVUS is the first and only therapy with six-month dosing approved for both relapsing MS (RMS), (including RRMS and active, or relapsing, secondary progressive MS) and primary progressive MS (PPMS). Additionally, new safety data presented at AAN representing 4,501 patients with RMS and PPMS and 12,559 patient years of exposure to OCREVUS, across all OCREVUS clinical trials, remain consistent with the medicine’s favorable benefit-risk profile.
“These are the first data to show that higher OCREVUS exposure is associated with greater control of disability progression without impacting safety,” said Stephen Hauser, M.D., chair of the Scientific Steering Committee of the OPERA studies and director of the Weill Institute for Neurosciences at the University of California, San Francisco. “These analyses, along with long-term data that show OCREVUS reduced the risk of permanent disability progression, create a compelling case for initiating therapy early in the disease course and provide important information that clinicians can use to inform treatment decisions.”
New data from pharmacokinetic, pharmacodynamic and exposure analyses – or how OCREVUS is processed in an individual’s body over time – show higher exposure to OCREVUS correlated with lower B-cell levels and lower rates of disability progression in patients. In patients with RMS, OCREVUS reduced the risk of 24-week confirmed disability progression (CDP) at all exposure levels compared with interferon beta-1a. There was lower risk of disability progression with higher exposure to OCREVUS.


Article Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

The Benefits of RECEPT Broad Spectrum Hemp Extract

2018 was a breakthrough year for hemp extract and cannabidiols. From capsules, tinctures and pumps to patches, edibles, drinks, and pet products—the hemp extract and CBD market made a household name for itself this past year—a $600 million name in fact. With hemp extract and CBD’s rise in nationwide popularity, an influx of new companies and products have made their way to the market. And that growth isn’t expected to slow, as data forecasts project the hemp-derived CBD industry will reach $22 billion by 2022.
A pioneer in the industry before it was “trendy”; PrimeMyBody is now a mainstay on the hemp oil and extract market. We have a responsibility to our Affiliates, customers, and the entire market to offer premium products that harness and effectively deliver the natural benefits hemp so readily provides. That mission led us to the development of RECEPT broad spectrum hemp extract.
 A New Hemp Extract Experience
To be a leader in this new age of hemp health you have to take forward-thinking approaches to product development. RECEPT is a statement to the metamorphosing hemp market. It is a declaration that room for improvement is always open, that unlocking hemp’s seemingly limitless health potential is an ongoing affair.
With guidance from our Chief Medical Advisor, Dr. Cheng Ruan, we took calculated measures to decipher how a hemp and phytocannabinoid product could be improved and made better. For us it started with expanding the phytocannabinoid and terpene profile as a way to develop a more well-rounded entourage effect.
Simply put, an entourage effect is the concept that various compounds in the hemp plant work best when synergized together, rather than being isolated. This orchestra of compounds all harmoniously playing together organically promotes more impactful health results.
“The focus on cannabidiol or CBD has probably been the most famous and most studied, up until now. We wanted to recognize that the entourage effect is going to have a more powerful effect on the human system and also have a more natural effect,” says Dr. Ruan.
“RECEPT is about something the body is able to utilize to balance itself. It’s all about balance and equilibrium these days. That’s where the hemp industry is going and why we wanted to be ahead of the curve with RECEPT.”

A Spotlight on CBG (Cannabigerol)

A key phytocannabinoid that contributes to a complete entourage effect is CBG or cannabigerol. Overshadowed culturally by CBD and THC, CBG is a rising star in the hemp and wellness field. “A focus it seems now is pharmaceutical companies are taking note of its benefits and starting to purchase plots of land for the making of CBG-heavy hemp plants in preparation of doing their own clinical trials,” adds Dr. Ruan.
A precursor or parent compound to many other phytocannabinoids like CBD and THC, CBG’s potential effects on health and wellness have only begun to be tapped. “CBG is a compound that we’re starting to see a tremendous amount of data on, especially toward the end of 2018,” says Dr. Ruan.
Continue reading



----------------------------------------------------                      
Article Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Phase 3 Trial Finds Tysabri Lowers Serum Neurofilament Light Levels in SPMS Patients

MAY 7, 2019 BY JOSE MARQUES LOPES, PHD

Treatment with Tysabri (natalizumab) lowers the levels of the biomarker serum neurofilament light chain (sNfL) in patients with secondary progressive multiple sclerosis (SPMS), according to data from a Phase 3 trial.
Findings also revealed that higher levels of sNfL correlated with MS lesions and disease activity prior to starting the therapy, and with the extent of future brain atrophy.
Hans-Peter Hartung, MD, presented the study, “Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study,” at the 2019 American Academy of Neurology (AAN) annual meeting, being held through May 10 in Philadelphia. Hartung is a professor and chairman of the department of neurology at Heinrich Heine University in Germany.
Although not specific to MS, sNfL has been proposed as a biomarker of nerve cell damage, disease activity, and treatment response in relapsing-remitting MS (RRMS). However, the potential of sNfL as a biomarker in SPMS patients is unclear.
Aiming to address this, the team of researchers evaluated the link between sNfL levels and disease activity, disability progression, and response to Biogen’s Tysabri in patients who had had SPMS for at least two years and who participated in the Phase 3 ASCEND trial (NCT01416181).


----------------------------------------------------                      
Article Provided by:  #MSViewsandNews
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Tuesday, May 7, 2019

Copaiba for Orthopedic Pain Relief

If you are looking for a natural product to help you with pain, you may want to consider doTERRA Copaiba. Copaiba essential oil is derived from the resin of the copaiba tree  and can be found in tropical South America. This is a non-THC product.

Copaiba essential oil supports the health of the cardiovascular, immune, digestive, nervous, and respiratory systems. Although Copaiba does not contain psychoactive cannabinoids, the main component caryophyllene may be neuroprotective and have cardiovascular and immune benefits. 


If you would like to purchase, click on the link below.  
If you have questions, please email Lisa Jurecko at belevatedoils@gmail.com


http://www.doterra.com/US/en/create-cart/enrollment?OwnerID=602503&acctType=WC&60207659=1&60202178=1




Disclaimer:
Though Copaiba has worked for Stuart, with many of his orthopedic problems we ask that you all
please consult with your healthcare provider before trying any new substance mainstream or complementary.

'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly
.................................................

Sunday, May 5, 2019

The Evolving Role of Patient Advocates


While pharma has long had relationships with advocacy organizations, there is a growing wave of individual patients who are willing to speak up, be engaged, and provide insights to help the industry identify opportunities to improve both the patient experience and care.


https://www.pharmavoice.com/editors-choice-pdf/evolving-role-patient-advocates/


                    
Article Provided by:  #MSViewsandNews
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Multiple Sclerosis Symptoms Video: Swollen Legs and Feet. If you're impacted by MS and suffer from swollen feet





::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

To receive The MS BEACON, e-Newsletter, Click here
------------------------------------------------------
CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 
Click Red Box on banner to opt-in
----------------------------------------------------                      
Article Provided by:  #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

The 2019 Ohio Health MS Symposium, including NeuroFilaments, Bladder, PT, Vitamins,Medical Cannabis, and more

 
                      MS Symposium - March 2, 2019


NOW found on the MS Views and News Learning channel on YouTube (http://www.youtube.com/msviewsandnews)
Please Find Parts 1, 2 and 3 -  of the first OhioHealth MS Symposium, that took place on 03.02.19 ---

This educational program (in three parts) includes hot topics from Jacqueline Nicholas, MD on NeuroFilament Light Chain; Carina Siracusa, PT, DPT on Pelvic Floor exercise, Geoffrey Eubanks on Supplements used in MS. From Jessica Petitti, PT, DPT on Neuro-Wellness and Exercise/Goal Planning, Ketul Shah, MD on Bladder issues in relation to MS, Jeffrey A. Segal, NSCA-CPT, CSCS, CPTS, CPR/AED on Stretching and Strengthening, Traci Paxton, LISWs who discusses Connecting the Emotional Impact of MS AND from Aaron Boster, MD who skillfully describes an extremely interesting topic of Cannabis, in MS…

Interactive Q&A with the audience and all (8) Presenters can be watched and listed-to, following Dr. Boster's talk on Medical Cannabis (in part 3)

to watch all (3) parts to this first OhioHealth MS Symposium.
   Part 1 -- https://youtu.be/If_uDmgyGlk    --    






This 2019 OhioHealth MS Symposium was Planned, Implemented, choreographed and video recorded by  #MSViewsandNews

Note: To register for the monthly MS Views and News MS Neuro TV webinar series, click here to sign-up: https://bit.ly/2YdzaqR 
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::